RUNX2 and colorectal cancer: High CBX4 expression and low RUNX2 levels are associated with improved survival in colorectal cancer patients, suggesting that enhancing the CBX4-HDAC3 axis could serve as a potential therapeutic strategy for managing metastasis in colorectal cancer [92].